|Biotech Due Diligence||
This post will highlight comments on the Sanofi $SNY year-end 2012 conference call relevant to Isis Pharmaceuticals $ISIS, partner for the development and commercialization of KYNAMRO (mipomersen) for familial homozygous hypercholesterolemia.
This post features comments from the Teva Pharmaceuticals $TEVA year-end 2012 earnings conference call that are relevant to companies covered here at BiotechDueDiligence.
As usual the discussion centers COPAXONE for multiple sclerosis, which Momenta Pharmaceutical $MNTA and partner Sandoz (Novartis $NVS) are seeking approval for a generic version of.
MNTA and biosimilars - notes from other biotech/pharma conference calls
Other blog posts related to TEVA and MNTA
This post will highlight updates provided on the Merck $MRK 4q-2012 earnings conference call related to the MK-8931 BACE inhibitor program partnered with Ligand Pharma LGND for Alzheimer's Disease.
Info from Merck R&D presentation about MK-8931
MK-8931 data presented at 2012 AAIC conference
Links of interest regarding drug discovery against the BACE target
Merck announces phase 2/3 plans for MK-8931
This afternoon, investors, patient advocates, and the cancer research community get their first glimpse at clinical data from an RNAi therapeutic targeting polo-like kinase 1 (PLK1), in development by Tekmira Pharmaceuticals $TKMR. Preliminary phase 1 safety and efficacy data are being presented by Dr. Ramesh Ramanathan at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.
Orphan Diseases: Rare Rivalry
Tanya Lewis - Medical Marketing and Media (h/t @bradloncar)
On AEGR Juxtapid (lomitapide) and SNY ISIS Kynamro (mipomersen) in homozygous familial hypercholesterolemia.
Gilead Sciences Building on HIV, Becoming Cancer [and inflammation] Drug Force
Luke Timmerman (Xconomy)
Novartis, Gleevec, and Indian patents? An odd trifecta for a big news story, here are some details from various perspectives...
Novartis press release
New York Time article
In the Pipeline blog (Derek Lowe)
SEC’s New Social Media Guidance: Sensible, Fair, Inevitable
Brad Loncar (Xconomy)
Myths In The Pricing Of New Drugs
John LaMattina (Forbes)
Biosimilars are not similar enough: a proposal for true "biogenerics"
Drug Baron blog
Calls for mandatory licensing of production info after an exclusivity period as alternative to current biosimilar pathways.
Fewer ODAC Meetings? It's not your imagination!
Peggy Eastman (Oncology Times) with comments from Richard Pazdur
Leading Health-care Organizations Issue Guideline Recommendations for Molecular Testing and Targeted Therapies
The ASCO Post
New recommendation: ALL advanced lung adenocarcinoma patients should be screened for EGFR and ALK mutations.
Your support is greatly appreciated